Supporting global industrial scale-up at a pandemic speed with Type 1 pharma glass containers and timely solutions
In a compressed timeframe, producing large quantities of pharmaceutical glass containers to deliver the coronavirus vaccine around the world is a critical factor for a successful global response. Type 1 glass is a proven and widely available solution for pharma glass containers that preserves the stability of vaccines. Players in the pharmaceutical supply chain are committed to supporting pharmaceutical companies and governments in the fight against the pandemic.
From the beginning of the coronavirus, Stevanato Group, as a leading producer of glass primary packaging and provider of integrated capabilities for drug delivery systems based in Italy, increased its worldwide production capacity of glass containers to secure SARS-CoV-2 treatments and vaccines while protecting its staff.
The company has implemented health and safety measures according to national and regional regulations and maximized the use of remote working and communication systems in all its global operations.
Ensuring the timely supply of high-quality glass primary packaging, technologies and services at a pandemic speed
Conscious of its essential role in addressing the public health emergency, Stevanato Group deployed all its available assets to ensure the timely supply of its integrated offering to healthcare companies. They range from high-quality glass primary packaging, also sterilized, plastic consumables for diagnostic kits for virus detection, advanced analytical testing, visual inspection systems of filled containers, and packaging equipment.
For more information on the integrated offering, click here
Stevanato Group has also potentiated its digital tools to assist pharmaceutical companies in these times of reduced travel and social distancing, implementing remote FAT and SATs and remote virtual audits.
A dedicated coronavirus taskforce has been active since the beginning of the pandemic to address any commercial inquiry and identify the best suited and timely solution.
Moreover, confirming its strong commitment to the territory in which it was born, Stevanato Group decided to donate an initial amount of EUR 500,000 to support a multitude of healthcare structures operating in the Veneto region.
A significant contribution to the fight of the pandemic: the agreement with CEPI
Last June, Stevanato Group signed an agreement with the Coalition for Epidemic Preparedness Innovations (CEPI), the global partnership at the forefront of funding and coordinating the development of COVID-19 vaccine candidates. The agreement foresees the provision of 100 million pharma glass vials manufactured at its facilities in Italy and Mexico for up to 2 billion doses of COVID-19 vaccines under development and a "fast track" access to Stevanato Group glass forming lines provided by its company Spami.
CEPI is currently investing up to US $829 million in nine SARS-CoV-2 vaccine candidates.
Built on the principles of speed, scale, and access, CEPI's diverse coronavirus vaccine portfolio includes many modern and innovative approaches to increase the world's chances of finding a safe, effective, and globally accessible vaccine. The goal is to speed up development of a successful vaccine to an accelerated 12-18-month timeframe.
Stevanato Group - which produces annually 10 billion units among drug delivery systems, sterile and bulk glass containers, plastic diagnostic and medical components, including proprietary products - has become a key supplier to CEPI’s COVID-19 vaccine programmes.
Related News
-
News Accepting novel excipients for innovative drug development
With the rapid development and manufacturing of new drugs and therapeutics being pushed through the pipeline, excipient manufacturers are navigating a challenging landscape to meet the demand for new and novel excipients. -
News Biosimilars save patients $11B annually, but barriers to adoption remain in US market
Biosimilars introduce competition into the biologics market, driving down prices and increasing patient access. -
News Connect to Frankfurt - Five reasons to tune in
Get a jump-start on your CPHI Frankfurt experience with exclusive access to our online event platform. -
News WHO calls on public for ideas to rename monkeypox
‘Poxy McPoxface’, ‘TRUMP-22’, and ‘Mpox’ are just some of the suggestions submitted by the public -
News Chinese market represents ‘single greatest generational opportunity’ for Pharma
China’s pharmaceutical industry is changing from formerly generics-focused into one that emphasizes innovation, spurred by shifting government policy and an aging population. -
News Monkeypox Update: Vaccine shortage, sewage surveillance and global testing
As concern over the monkeypox outbreak continues to rise, we take a look at major developments from the first week of August. -
News mRNA production partnership to scale-up COVID-19 vaccine development
GreenLight Biosciences and Samsung Biologics announce mRNA production partnership to scale mRNA vaccine production to a commercial level with Samsung's expanded mRNA drug substance manufacturing site. -
News The Data Revolution: How Real-World Evidence is Changing Pharma
A look at the companies extracting valuable insights from health data to accelerate clinical development and support regulatory decision making.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance